


CASE REPORT

Open Access



Rare presentation of an atrial myxoma in an adolescent patient: a case report and literature review

Eduardo Macias^{1*} , Elizabeth Nieman², Kentaro Yomogida³, Orlando Petrucci⁴, Cylen Javidan⁵, Kevin Baszis³ and Shafkat Anwar¹

Abstract

Background: Cardiac tumors are uncommon in the pediatric population. When present, cardiac manifestations stem from the tumor causing inflow or outflow obstruction. While common in adults, cardiac myxomas presenting with generalized systemic illness or peripheral emboli especially with no cardiac or neurological symptoms are rare in children.

Case presentation: We report a case of a previously healthy adolescent girl who presented with a 6-month history of constitutional symptoms and a purpuric rash with no cardiac or neurologic symptoms, found to have a cardiac myxoma.

Conclusions: A vasculopathic rash in the setting of atrial myxomas has been shown to be a precursor to significant morbidity and mortality. Due to the rarity of this entity, the time elapsed from onset of non-cardiac symptoms until diagnosis of a myxoma is usually prolonged with interval development of irreversible neurological sequelae and death reported in the literature. Therefore, we highlight the importance of including cardiac myxomas and paraneoplastic vasculitis early in the differential diagnosis for patients presenting with a purpuric rash and systemic symptoms.

Keywords: Myxoma, Purpuric rash, Systemic symptoms, Neurological sequelae, Paraneoplastic vasculitis, Embolic phenomena

Background

Cardiac tumors are rare in the pediatric population, found in less than 0.5% of children evaluated for cardiac disease [1]. Atrial myxomas are the most common cardiac tumor in adults, most commonly presenting with cardiac symptoms. Embolic phenomena, and constitutional or systemic signs [2, 3] follow cardiac symptoms in frequency. In pediatrics, myxomas comprise less than 15% of cardiac tumors [1, 4–6] and presentation with non-cardiac, constitutional symptoms is rare. Thus, we report a case of an adolescent girl who presented with a rash, fever, purpura, and elevated inflammatory markers found to have a cardiac myxoma.

Our case establishes a unique precedent of a diagnosis of cardiac myxoma manifesting with systemic symptoms and a vasculopathic rash, but no neurological embolic phenomena.

Case presentation

A 13-year-old previously healthy girl presented to the emergency department (ED) for evaluation of fever, bilateral foot pain, and rash. Her symptoms began 6 months prior to presentation, occurring 1–2 times per month, lasting for 2–3 days, and improving with ibuprofen. A few weeks prior to ED presentation, she noted onset of fatigue, pain in her hip and calf, which she attributed to her competitive soccer playing, and acute abdominal pain with diarrhea and emesis.

Patient denied fever, headaches, visual changes, oral ulcers, muscle pain, or changes in bowel and bladder

* Correspondence: e.macias@wustl.edu

¹Division of Cardiology, Department of Pediatrics, Washington University School of Medicine in St. Louis, One Children's Place, Campus Box 8116-NWT, St. Louis, MO 63110, USA

Full list of author information is available at the end of the article





Fig. 1 Skin findings at presentation, including retiform patches, purpura and duskiness of right 2nd toe. Left foot dorsum with biopsy sutures in place

functions. She had no other medication use or recent travel. Her family history was negative for autoimmune diseases.

Her vital signs upon presentation showed a temperature of 39.2 degrees Celsius, heart rate of 90 beats per minute, respiratory rate of 20 breaths per minute, blood pressure of 114/62 mmHg, and 97% oxygen saturation on room air. She had a blanchable, retiform, violaceous patches with few areas of true purpura on her bilateral lower extremities and duskiness of her right second toe (Fig. 1). The remainder of her physical exam was unremarkable: a regular heart rate and rhythm with normal S1, S2 and no murmurs, rubs, or gallops; 2+ symmetric peripheral pulses; and joints with full range of motion without effusion or warmth. Her neurological exam was normal with no focal deficits. Her inflammatory markers were elevated (Table 1) and she was admitted for further evaluation.

Initial diagnostic considerations were vasculitis, including cutaneous polyarteritis nodosa, leukocytoclastic vasculitis (associated with lupus erythematosus, infection or idiopathic), versus a vasculopathy due to anti-phospholipid antibody syndrome, cryoglobulinemia, coagulopathy or septic emboli (Table 2).

Skin biopsy of a non-palpable purpuric area on the dorsum of her left foot demonstrated subtle ischemia, vascular congestion, purpura, and focal eccrine gland necrosis without evidence of vasculitis, which was concerning for a vasculopathic process. Direct immunofluorescence of the skin biopsy was negative. Extensive systemic

work-up was unremarkable and included: hepatitis panel, cryoglobulins, lupus anticoagulant panel, cardiolipins, beta-2-microglobulin, beta-2-glycoprotein, complements 3 and 4, antistreptolysin O (ASO) titers, anti-DNAse B, and aldolase. Abdominal and renal Doppler ultrasounds were also unremarkable.

During her hospital course, she developed recurrent fevers that were treated with acetaminophen at typical doses. In addition, she received a 1-time dose IV methylprednisolone 1 mg/kg after her battery of laboratory tests and skin biopsy.

An echocardiogram was performed to screen for intra-cardiac thrombus and assess for coronary abnormalities due to concerns for vasculitis. The echocardiogram revealed a 2.5 by 3-cm (cm) mass in the left

Table 1 Inflammatory markers at initial presentation

Laboratory	Value	Reference Range
Creatinine Kinase	1076	< 300 U/L
LDH	1216	100-250 U/L
CRP	48.8	< 10.0 mg/L
ESR	16	< 20.0 mm/hr
AST/ALT	164/89	10-50 U/L; 10-40 U/L
GGT	14	5-35 U/L
IL-6	< 0.5 ng/ml ^a	

Abbreviations: LDH lactate dehydrogenase, CRP C-reactive protein, ESR erythrocyte sedimentation rate, AST aspartate transaminase, ALT alanine transaminase, GGT gamma-glutamyl transferase, // Interleukin

^aLevel drawn 6 days after initial presentation and 4 days after a IV dose of methylprednisolone

Table 2 Differential diagnosis

Rheumatologic/ hematologic	Neoplastic	Infectious	Cardiac
Polyarteritis nodosa	Paraneoplastic vasculitis	Septic emboli	Cardiac myxoma
Leukocytoclastic vasculitis, inflammatory		Leukocytoclastic vasculitis	
Coagulopathy (i.e., antiphospholipid syndrome, cryoglobulinemia, other inherited disorder)			
Henoch-Schonlein purpura			

atrium (LA), Fig. 2. Cardiac magnetic resonance was performed for tissue characterization of the LA mass [7] and showed a 2.7 × 2.3 cm lobulated and mobile mass within the left atrium adherent to the septum (Fig. 2), consistent with a left atrial myxoma.

The patient's rash and constitutional symptoms were attributed to the myxoma. Purpura and pain in the right toe was felt to be secondary to either micro-embolic phenomenon or vasospasm. The decision was made to proceed with surgical excision of the cardiac mass. She was observed off anticoagulation given the lack of any concerning neurologic symptoms until surgery, which followed shortly thereafter.

The patient underwent an uncomplicated surgical resection and the diagnosis of cardiac myxoma was confirmed histologically (Fig. 3). She had an uncomplicated post-operative course with resolution of fevers and systemic symptoms in the immediate post-operative period. At 3-week follow-up she continued to be afebrile with near complete resolution of her skin findings (Fig. 4). She had no concerning symptoms at her 8-month follow up.

Discussion and conclusions

Cardiac tumors are rare in children with an incidence of 0.17–0.2% [8, 9]. The most common pediatric cardiac tumors are rhabdomyomas [1, 4, 5, 10–12], 10% of which are familial and associated with Carney complex [6]. Cardiac myxomas have been diagnosed more frequently with the advent of echocardiography [3] and are most commonly located in the left atrium [5]. In children, the mean age of diagnosis is 9–10 years [5, 13]. Delayed or undiagnosed cardiac myxomas can result in severe or fatal complications due to embolization of these friable tumors or cardiac obstruction [14, 15].

As illustrated by our patient's recurrent fevers, fatigue, skin findings and elevated inflammatory markers, cardiac myxomas can present with variable clinical symptoms that mimic other conditions (Table 2). Extracardiac manifestations are often caused by embolic phenomena and inflammation due to the intrinsic secretion of cytokines. In a series of 112 cases in adults, 34% of patients presented with systemic or constitutional symptoms and 16% presented with embolic manifestations [3]. However, review of the literature reveals only 6 reported cases of pediatric cardiac myxomas presenting with systemic symptoms without cardiac manifestations [15–21] and no cases of distal emboli without concurrent neurologic symptoms from cerebral emboli. Our case's unique presentation with both systemic symptoms and vasculopathy (possibly due to emboli or vasospasm) highlights the importance of early recognition of the many features of these tumors to prevent to morbidity and mortality related to emboli.

A case series of children with cardiac myxomas causing cerebral emboli emphasizes the need for expedient diagnosis of cardiac myxomas; 6 out of 9 of these children had residual neurologic deficits and 1 died post-operatively [22]. Several of these children had distal extremity skin lesions noted before their neurologic events, demonstrating that earlier diagnosis




Fig. 2 Echocardiographic image in the apical four chamber view shows a pedunculated mass attached to the atrial septum, red arrow. Cardiac magnetic resonance imaging study, the axial four-chamber view shows the left atrial mass. Tissue characterization with T1 and T2 weighted images, first pass gadolinium perfusion and delayed enhancement sequences was highly suggestive of a myxoma



Fig. 3 3.5 X 3.5 X 2.5 lobular, gelatinous, myxomatous mass following resection from left atrium in the operating room. Microscopic examination substantiated the diagnosis of a myxoma

is possible with an elevated index of suspicion. Interestingly, none of these cases had associated systemic symptoms or significantly elevated inflammatory markers as our patient did, indicating that we cannot attribute all of her symptoms to embolic phenomena and consider inflammation intrinsic to the myxoma as well (Table 3).

Cardiac myxoma is known to secrete pro-inflammatory cytokine interleukin 6 (IL-6) and serum IL-6 plasma level is correlated with constitutional symptoms [23]. Serum IL-6 level was normal in our case but this was examined after IV methylprednisolone was initiated. A previous report demonstrated that 11 out of 12 patients (92%) with cardiac myxoma related vasculitis experienced improvement of symptoms with steroid administration, thus her normal IL-6 level likely reflected prior steroid therapy [2].

Paraneoplastic vasculitis is an under recognized diagnosis, occurring in 5.2% of vasculitis cases [24]. Given the rarity of the concurrent conditions, diagnosis of malignancy is often delayed and the mean interval before diagnosis of malignancy is reported to be 11.9 months. A diagnosis of vasculitis requires rheumatological and infectious investigation, but search for malignancy is mandatory when clinical course becomes chronic and refractory to conventional therapy. While there have been several case series of cardiac myxomas mimicking vasculitis in adults and 2 reports in children and 2 reports in children [2], our patient did not have any evidence of vasculitis on biopsy, making it unlikely that systemic inflammation was the etiology of our patient’s distal skin findings.

In our case, systemic vasculitis and vasculopathy were the initial diagnostic considerations given our patient’s systemic symptoms and distal purpura. An echocardiogram quickly



Fig. 4 Resolution of purpura with minimal residual erythema at the right second toe 3 weeks after resection




Fig. 5 Timeline

Table 3 Review of non-cardiac presentations of cardiac myxomas in the pediatric literature

Reference	Number of patients; age (years)/ Gender	Systemic symptoms	Embolic signs	Elevated IL-6
Xu [25]	1;13/F	None	Headache	NA
Goldberg [15]	1; 3/M	None	Right hemiparesis, red spots on foot; died	NA
Omeroglu [26]	2; 4/F, 6/F	None	Stroke	NA
Al-Mateen [22]	2; 11/F, 10/M	None	Acute hemiplegia, transient ischemic attack, red spots	NA
Hovels [16]	1; 6/F	Fever, arthralgia	None	yes
Park [17]	1; 5/M	Vasculitis	None	NA
Shiraishi [18]	1	Fever	none	NA
Patel [20]	1;17 /M	Fatigue; rash	none	NA
Kaminsky [21]	1;14/M	Arthropathy	None	NA
Saji [19]	1	NA	NA	NA
Domanski [27]	1; 8/M	None	Stroke	NA
Tipton [28]	1; 17/M	None	Right hemiparesis, lethargy	NA
Bobo [29]	1; 15/F	None	Right hemiparesis, headache	NA
Tonz [30]	1; 8/M	None	Right hemiparesis, seizures, aphasia, red spots, retinal artery occlusion	NA
Hung [31]	1; 10/F	None	Right hemiparesis, retinal artery occlusion	NA
Bayir [32]	1; 14/F	None	Right hemiparesis, aphasia, slurred speech, cool right leg	NA
Landers [33]	1; 8/F	None	Right hemiparesis, expressive aphasia, pulmonary embolus	NA
Macias	1;13/F	Fever, fatigue	Purpura/distal emboli	No

Embolic signs include stroke, purpura, retinal artery occlusion. Systemic symptoms include fever, arthralgia, and fatigue. NA not applicable as not evaluated or not mentioned in work up

raised high suspicion for cardiac myxoma, supported by tissue characterization by MRI. This allowed for expedient tumor resection and improvement of symptoms (Fig. 5). This case emphasizes the importance of considering a cardiac myxoma in a patient with both systemic inflammation and vasculopathic phenomena.

Abbreviations

ALT: Alanine transaminase; AST: Aspartate transaminase; CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate; GGT: Gamma-glutamyl transferase; IL: Interleukin; LDH: Lactate dehydrogenase

Acknowledgements

The authors wish to acknowledge Dr. Carrie Coughlin, Washington University in St. Louis, School of Medicine, Division of Dermatology for her expert consultation and advice on this case report.

Funding

None.

Availability of data and materials

All data generated or analysed during this study are included in this published article and its supplementary information files.

Authors' contributions

SA conceptualized and designed the case report, reviewed and revised the manuscript, and approved the final manuscript as submitted. EM developed initial draft, reviewed and revised the manuscript, and approved the final manuscript as submitted. EN developed initial draft, revised the manuscript, and approved the final manuscript as submitted. KY developed initial draft, revised the manuscript, and approved the final manuscript as submitted. OP developed initial draft, revised the manuscript, and approved the final manuscript as submitted. CJ developed initial draft, revised the manuscript, and approved the final manuscript as submitted. KB developed initial draft, revised the manuscript, and approved the final manuscript as submitted.

Ethics approval and consent to participate

Case Reports are not required to have Institutional Review Board approval, and thereby ethics approval at Washington University at Saint Louis School of Medicine.

Consent for publication

Our patient and patient's father signed a written consent for publication of her clinical information and her pictures according to Washington University at Saint Louis School of Medicine's internal policies and statutes.

Competing interests

The authors declare that they have no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Division of Cardiology, Department of Pediatrics, Washington University School of Medicine in St. Louis, One Children's Place, Campus Box 8116-NWT, St. Louis, MO 63110, USA. ²Division of Dermatology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA. ³Division of Rheumatology, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA. ⁴Division of Cardiothoracic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA. ⁵Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA.

Received: 12 April 2018 Accepted: 18 October 2018

Published online: 28 November 2018

References

- Linnemeier L, Benneyworth BD, Turrentine M, et al. Pediatric cardiac tumors: a 45-year, single-institution review. *World J Pediatr Congenit Heart Surg.* 2015;6(2):215–9. <https://doi.org/10.1177/2150135114563938>.
- Moreno M, Ortiz-Santamaria V, Deudero Infante A, et al. A classic mimicker of systemic vasculitis. *Reumatol Clin.* 2016;12(2):103–6. <https://doi.org/10.1016/j.reuma.2015.03.006>.
- Pinede L, Duhaut P, Loire R. Clinical presentation of left atrial cardiac myxoma. A series of 112 consecutive cases. *Medicine (Baltimore).* 2001;80(3):159–72.
- Marx GR, Moran AM. Cardiac Tumors. In: Allen HD, editor. *Moss & Adams' Heart Disease in Infants, Children, and Adolescents, Including the Fetus and Young Adult.* 9th ed. Philadelphia: Wolters Kluwer; 2016. p. 1669–79.
- Shi L, Wu L, Fang H, et al. Identification and clinical course of 166 pediatric cardiac tumors. *Eur J Pediatr.* 2017;176(2):253–60. <https://doi.org/10.1007/s00431-016-2833-4>.
- Jain S, Maleszewski J, Stephenson C, et al. Current diagnosis and management of cardiac myxomas. *Expert Rev Cardiovasc Ther.* 2015;13(4):369–75. <https://doi.org/10.1586/14779072.2015.1024108>.
- Beroukhi RS, Prakash A, Buechel ER, et al. Characterization of cardiac tumors in children by cardiovascular magnetic resonance imaging: a multicenter experience. *J Am Coll Cardiol.* 2011;58(10):1044–54.
- Freedom RM, Lee KJ, MacDonald C, et al. Selected aspects of cardiac tumors in infancy and childhood. *Pediatr Cardiol.* 2000;21(4):299–316.
- Sallee D, Spector ML, Van Heeckeren DW, et al. Primary pediatric cardiac tumors: a 17 year experience. *Cardiol Young.* 1999;9(2):155–62.
- Yadava O. Cardiac tumors in infancy. *Indian Heart J.* 2012;64(5):492–6. <https://doi.org/10.1016/j.ijhj.2012.05.004>.
- Barnes H, Conaglen P, Russell P, et al. Clinicopathological and surgical experience with primary cardiac tumors. *Asian Cardiovasc Thorac Ann.* 2014;22(9):1054–8. <https://doi.org/10.1177/0218492314528922>.
- Delmo Walter EM, Javier MF, Sander F, et al. Primary Cardiac Tumors in Infants and Children: Surgical Strategy and Long-Term Outcome. *Ann Thorac Surg.* 2016;102(6):2062–9. <https://doi.org/10.1016/j.athoracsur.2016.04.057>.
- Bielefeldt KJ, Moller JH. Cardiac tumors in infants and children: study of 120 operated patients. *Pediatr Cardiol.* 2013;34:125. <https://doi.org/10.1007/s00246-012-0399-034>.
- Animasahun AB, Kushimo OY, Fajuyile FA, et al. Atrial myxoma in 2 nigerian children: case reports and review of the literature. *World J Pediatr Congenit Heart Surg.* 2010;1(3):397–9. <https://doi.org/10.1177/2150135110381390>.
- Goldberg HP, Glenn F, Dotter CT, et al. Myxoma of the left atrium: diagnosis made during life with operative and post-mortem findings. *Circulation.* 1952;6:762–7.
- Hövels-Gürich HH, Seghaye MC, Amo-Takyi BK, et al. Cardiac myxoma in a 6-year-old child—constitutional symptoms mimicking rheumatic disease and the role of interleukin-6. *Acta Paediatr.* 1999;88(7):786–8.
- Park JM, Garcia RR, Patrick JK, et al. Right atrial myxoma with a nonembolic intestinal manifestation. *Pediatr Cardiol.* 1990;11(3):164–6.
- Shiraishi I, Yamagishi M, Kato R, et al. A case in a child of giant left-atrial myxoma associated with recurrent high fever and myxoma cells expressing interleukin-6. *Eur J Pediatr.* 2006;165(5):346–7.
- Saji T, Matsuo N, Shiono N, et al. Serum/tissue interleukin-6 concentrations and constitutional abnormalities in 4 patients with cardiac myxoma. *Kokyu To Junkan.* 1993;41(9):891–5 [Article in Japanese].
- Patel R, Lynn KC. Masquerading myxoma. *Am J Med Sci.* 2009;338:161–3.
- Kaminsky ME, Ehlers KH, Engle MA, et al. Atrial myxoma mimicking a collagen disorder. *Chest.* 1979;75(1):93–5.
- Al-Mateen M, Hood M, Trippel D, et al. Cerebral embolism from atrial myxoma in pediatric patients. *Pediatrics.* 2003;112(2):e162–7.
- Parisis JT, Mentzikof D, Georgopoulou M, et al. Correlation of interleukin-6 gene expression to immunologic features in patients with cardiac myxomas. *J Interf Cytokine Res.* 1996;16(8):589–93.
- Fain O, Hamidou M, Cacoub P, et al. Vasculitides associated with malignancies: analysis of sixty patients. *Arthritis Rheum.* 2007;57(8):1473–80.
- Xu J, Gao Y, Li Y, et al. Left Atrial Myxoma Presenting as Headache in the Pediatric Patient. *J Emerg Med.* 2015;48(2):161–4.
- Omeroglu RE, Olgar S, Nisli K, et al. Recurrent Hemiparesis Due to Anterior Mitral Leaflet Myxomas. *Pediatr Neurol.* 2006;34(6):490–4.

27. Domanski O, Dubois R, Jegou B. Ischemic Stroke due to a Cardiac Myxoma. *Pediatr Neurol.* 2006;65:94–5.
28. Tipton K, Robertson JT, Robertson JH. Embolism to the central nervous system from cardiac myxoma. Report of two cases. *J Neurosurg.* 1977;47(6):937–40.
29. Bobo H, Evans OB. Intracranial aneurysms in a child with recurrent atrial myxoma. *Pediatr Neurol.* 1987;3(4):230–2.
30. Tönz M, Laske A, Carrel T, et al. Convulsions, hemiparesis and central retinal artery occlusion due to left atrial myxoma in child. *Eur J Pediatr.* 1992;151(9):652–4.
31. Hung PC, Wang HS, Chou ML, et al. Multiple cerebral aneurysms in a child with cardiac myxoma. *J Formos Med Assoc.* 1992;91(8):818–21.
32. Bayir H, Morelli PJ, Smith TH, et al. A left atrial myxoma presenting as a cerebrovascular accident. *Pediatr Neurol.* 1999;21(2):569–72.
33. Landers C, Baumann R, Cottrill MC, et al. Embolic strokes in an 8-year-old girl. *Neurology.* 2000;55(1):146. <https://doi.org/10.1212/WNL.55.1.146>.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

